Zafgen (ZFGN) Misses Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. NVDA
6. MSFT
7. SPY
8. SKYD
9. CRWV
10. CRBU

Go back to Zafgen (ZFGN) Misses Q4 EPS by 5c

Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results

March 9, 2016 4:06 PM EST

BOSTON, March 09, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq: ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its fourth quarter and full year 2015 financial results, and provided an update on the Companys clinical program for beloranib.

In recent months, we have reported compelling efficacy data from the ZAF-311 and ZAF-203 trials, providing additional context on the efficacy-safety profile of beloranib in severe obesity indications, and we are actively working to determine a path forward for beloranib... More